MODERN APPROACHES TO TARGETED THERAPY OF GASTROINTESTINAL STROMAL TUMORS: RESULTS OF A CLINICAL STUDY
DOI:
https://doi.org/10.54890/1694-8882-2025-3-166Abstract
This article presents the results of a prospective clinical study conducted at the National Center of Oncology and Hematology of the Kyrgyz Republic. The aim of the study was to assess the clinical efficacy and safety profile of targeted therapy for gastrointestinal stromal tumors (GIST) using imatinib (Glivec). The study included 70 patients with histologically and immunohistochemically confirmed diagnosis of GIST. All patients received imatinib at a standard dose of 400 mg/day until disease progression or intolerance. A partial response was achieved in 70% of patients, 15% showed disease stabilization, and 10% had disease progression. Grade III–IV adverse events were observed in 20% of patients, while most tolerated the therapy well. The most common side effects were edema, fatigue, and skin rash. Median progression-free survival was 14 years in patients under 65 and 5 years in older patients. The study substantiates the use of imatinib as a first-line therapy for GIST, particularly in patients with KIT and PDGFRα sensitive mutations. Molecular diagnostics improve treatment outcomes and reduce resistance risks. The findings are consistent with international guidelines and support the role of imatinib in modern oncological practice.
Keywords:
Gastrointestinal stromal tumour; Imatinib mesylate therapy; Progression-free survival; CTCAE toxicity; Tumour localization; Clinical outcomesReferences
1. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2021;398(10310):429–442. https://doi.org/10.1016/S0140-6736(21)00126-9
2. Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol. 2020;12:1758835920926130. https://doi.org/10.1177/1758835920926130
3. Kang YK, Joensuu H, Wu J, et al. Avapritinib versus regorafenib in advanced gastrointestinal stromal tumor after two or more kinase inhibitors (VOYAGER): a randomized, phase 3 trial. Lancet Oncol. 2021;22(7):958–968. https://doi.org/10.1016/ S1470-2045(21)00192-2
4. Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20–33. https://doi.org/10.1016/j.annonc.2021.09.005
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
6. Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021;7(1):22. https://doi.org/10.1038/s41572-021-00257-0
7. Liu Q, Wang Y, Liu S, et al. Clinical outcomes and resistance mechanisms of imatinib in GIST: a real-world retrospective analysis. Front Oncol. 2023;13:1125372. https://doi.org/10.3389/fonc.2023.1125372
8. Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21(7):935–946. https://doi.org/10.1016/ S1470-2045(20)30269-2
9. Kang YK, George S, Jones RL, et al. Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI Stromal Tumor: a randomized, open-label phase III study. J Clin Oncol. 2021;39(28):3128–3139. https://doi.org/10.1200/ JCO.21.00217
10. Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20–33. https://doi.org/10.1016/j.annonc. 2021.09.005
11. Haller V, Reiff C, Hamacher R, et al. Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability. J Cancer Res Clin Oncol. 2024;150(11):489. https://doi.org/10.1007/s00432-024-05965-2
12. Bauer S, Heinrich MC, George S, et al. Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogeneous KIT/PDGFRA mutations in the phase III INVICTUS study. Clin Cancer Res. 2021;27(23):6333–6342. https://doi.org/10.1158/1078-0432.CCR-21-1864
13. Bauer S, Jones RL, Blay JY, et al. Ripretinib versus sunitinib in patients with imatinib (INTRIGUE): a randomized, open-label, phase III trial. J Clin Oncol. 2022;40(34):3918–3928. https://doi.org/10.1200/JCO.22.00294
14. Jones RL, Serrano C, von Mehren M, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021;145:132–142. https://doi.org/10.1016/j.ejca.2020.12.008
15. Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21(7):935–946. https://doi.org/10.1016/ S1470-2045(20)30269-2
16. Kang YK, Bauer S, Schöffski P, et al. Avapritinib vs regorafenib in molecularly unselected previously treated advanced gastrointestinal stromal tumor: results from the phase III VOYAGER trial. J Clin Oncol. 2021;39(27):3128–3139. https://doi.org/10.1200/JCO.21.00753
17. Evans EK, Gardino AK, Kim JL, et al. The pharmacology of avapritinib in the treatment of PDGFRA D842V–mutant gastrointestinal stromal tumor. Mol Pharm. 2019;16(10):419–428. https://doi.org/10.1021/acs.molpharmaceut.9b00346
18. Ren W, Qu C, Zhao W, Hu J, Wang W, Yang J. Efficacy and safety of avapritinib in treating unresectable or metastatic gastrointestinal stromal tumors: a phase I/II study. Oncologist. 2022;27(4):e300–e310. https://doi.org/10.1002/onco.13674
19. Raut CP, Espat NJ, Maki RG, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4(12):e184060. https://doi.org/10.1001/jamaoncol.2018.4060
20. Nishida T, Kang YK, Reichardt P, et al. Efficacy and safety of pimitespib in patients with advanced gastrointestinal stromal tumor: results from the phase III CHAPTER-GIST-301 trial. Clin Sarcoma Res. 2023;13:5. https://doi.org/10.1186 /s13569-023-00191-9
21. Agaram NP, Wong GC, Guo T, et al. Novel KIT exon 10 mutations in gastrointestinal stromal tumors: insights into primary resistance to imatinib. Mod Pathol. 2020;33(8):1555–1563. https://doi.org/10.1038/s41379-020-0529-3
22. Li J, Demetri GD, Nishida T, et al. Genetic heterogeneity and radiomics in gastrointestinal stromal tumor management. J Clin Oncol. 2023;41(7):789–800. https://doi.org/10.1200/JCO.23.00456
Downloads
Published
How to Cite
Issue
Section
